bioRxiv Science⌕ Search

Biology subjects

Kozono, D.

Publications and source records attributed to Kozono, D..

2 recordsLinked to original sources

Mechanistic modeling and machine learning identifies optimum radiotherapy schedules to prevent treatment-induced metastasis

Lung cancer patients often experience increased metastasis formation after radiotherapy. However, it is incompletely understood whether radiation affects the migratory behavior of tumor cells and how altered radiotherapy schedules might mitigate this risk. To address these questions, we performed live-cell microscopy experiments to profile changes in cell migration during radiation across 12 cancer cell lines and developed a predictive computational modeling platform describing tumor volume and dissemination during radiotherapy. Using this platform, we identified optimal fractionation schedules and then performed extensive in silico clinical trials, establishing that our optimized schedules substantially reduce metastatic seeding relative to the standard of care schedule. Training transformer models on the in silico clinical trial data enabled us to recover mechanistic parameters with high accuracy, demonstrating that the features determining optimal radiotherapy can be inferred from longitudinal tumor data. Our integrative predictive approach enables the rational design of optimum clinical trials across indications.

bioinformatics↗

Identify non-mutational p53 loss of function in human cancers

An accurate assessment of TP53s functional status is critical for cancer genomic medicine. However, there is a significant challenge in identifying tumors with non-mutational p53 inactivations that are not detectable through DNA sequencing. These undetected cases are often misclassified as p53-normal, leading to inaccurate prognosis and downstream association analyses. To address this issue, we build the support vector machine (SVM) models to systematically reassess p53s functional status in TP53 wild-type (TP53WT) tumors from multiple TCGA cohorts. Cross-validation demonstrates the excellent performance of the SVM models with a mean AUC of 0.9822, precision of 0.9747, and recall of 0.9784. Our study reveals that a significant proportion (87-99%) of TP53WT tumors actually have compromised p53 function. Additional analyses uncovered that these genetically intact but functionally impaired (termed as predictively reduced function of p53 or TP53WT-pRF) tumors exhibit genomic and pathophysiologic features akin to p53 mutant tumors: heightened genomic instability and elevated levels of hypoxia. Clinically, patients with TP53WT-pRF tumors experience significantly shortened overall survival or progression-free survival compared to those with TP53WT-pN (predictive normal function of p53) tumors, and these patients also display increased sensitivity to platinum-based chemotherapy and radiation therapy.

bioinformatics↗